After the company updated investors on its clinical-stage progress on Monday, shares in Geron Corp. (NASDAQ: GERN) have more than doubled, including a 10% increase today as of 11:45 a.m. EDT. Patients with life-threatening hematologic myeloid malignancies, including myelofibrosis, have limited treatment options and a poor prognosis, so there's a big need for new treatment options, such as Geron Corp.'s imetelstat, which is currently in phase 2 studies and licensed to Johnson & Johnson (NYSE: JNJ).IMAGE SOURCE: GETTY IMAGES.Continue reading